As Professor Joshua Burns PhD bids farewell to his time at the Sydney Children’s Hospitals Network, he leaves behind a 20 year long legacy of incredible work and transformative leadership.

As a part of the Navigator Project, a targeted nurse-led support service has helped Finn's family in navigating a rare disease diagnosis and treatment.

A new viral vector manufacturing facility being built in the Westmead precinct is set to change the treatment landscape for patients with genetic diseases, cancers and viral infections, enabling gene therapies to be trialled and delivered sooner.

The latest round of MRFF grants will further drive innovation and research across Kids Research into areas such as childhood asthma, cancer, Cerebral Palsy and trauma care.

The groundbreaking FIREFLY-1 trial tested the efficacy of oral drug, tovorafenib, in brain tumour patients with results showing a 50 per cent tumour shrinkage in two thirds of patients.

OCD BOUNCE, an Australian-first paediatric public health service, is helping to bridge the gap and advance treatment for young people living with obsessive-compulsive disorder.

The two-day event hosted discussions by leading experts of not only the latest scientific developments in paediatric advanced therapeutics, but also their clinical counterparts.

The Children’s Hospital at Westmead has launched a world-first clinical trial investigating the use of phage therapy to treat a chronic bacterial infection in children with cystic fibrosis (CF).

The Rett syndrome clinic at Westmead, a world leader in its field, is looking towards gene therapy research to treat the condition – giving hope to families like Abigail's for a brighter future.

The Biospecimen Research Services at The Childrens Hospital at Westmead is celebrating its 25th anniversary.

Three boys in NSW have become the youngest in the world to receive therapy for Duchenne muscular dystrophy in a world-first trial.

Hospital Scientist Dr Benjamin Nash has been awarded an AGRF grant to support his research journey, enabling his team access to long read sequencing technology.

Patients with difficult-to-treat bacterial infections across NSW will soon have better access to limb and life-saving therapy known as phage therapy, thanks to a $3.5 million funding boost announced by the NSW Government.

A world-first clinical trial has been launched at Sydney Children’s Hospital, Randwick for children with ependymoma – a rare and devastating form of paediatric brain cancer.

Steps are being taken by SCHN to improve equity of access and service management for those living with a rare disease via The Navigator Project.